News
Public · Published
Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain
Artelo Biosciences announced that Professor Saoirse O'Sullivan will present data on ART26.12, described as the first selective FABP5 inhibitor to enter human clinical studies, at the IASP 2026 World Congress on Pain in Bangkok on October 29, 2026.
Published:
Updated:
What happened
Artelo Biosciences announced that Professor Saoirse O'Sullivan will present data on ART26.12, described as the first selective FABP5 inhibitor to enter human clinical studies, at the IASP 2026 World Congress on Pain in Bangkok on October 29, 2026.
Confirmed
Global impact / market context
Presenting to thousands of pain specialists could raise awareness of Artelo's non-opioid pain approach among clinicians and potential partners. Greater visibility may support future collaboration or licensing talks, though it does not itself change revenue, costs, or the cash the company has available.
Analyst inference
Investors in small clinical-stage drug developers often watch conference presentations for signs of pipeline progress. A presentation is a visibility event, not a regulatory or trial result, so it does not by itself alter the probability of approval or the company's need to raise money.
Analyst inference
What to watch
- The presentation is scheduled for October 29, 2026, at the IASP World Congress on Pain in Bangkok, which runs October 26 to 30 and gathers pain professionals worldwide. Confirmed
- Artelo plans to advance ART26.12 toward a multiple ascending dose study, which means a trial that increases doses step by step to test safety and tolerability in humans. Proposed
- Watch whether the presented data draw partner or investigator interest, since such interest could influence future research funding or collaboration deals rather than immediate sales. Analyst inference
Affected assets
- SOL — Solana